Ly3841136 Sodium

4 trials 4 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

1 Sponsors

7 Countries

Phase III

Phase III: 4

Sponsors using this IMP

Eli Lilly & Co. 4

All trials

4 total

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting

2025-523659-73-00 Phase III 4 countries Eli Lilly & Co.
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3) Recruiting

2025-523769-11-00 Phase III 2 countries Eli Lilly & Co.
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Phase III 3 countries Eli Lilly & Co.
A Study of Eloralintide (LY3841136) in Participants with Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) Recruiting

2025-523658-15-00 Phase III 5 countries Eli Lilly & Co.

Showing 1–4 of 4 trials

← All drugs A–Z